Etienne Giroux-Leprieur
Overview
Explore the profile of Etienne Giroux-Leprieur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vera P, Giraud P, Hapdey S, Gouel P, Jan O, Le Roux P, et al.
J Nucl Med
. 2025 Feb;
PMID: 40015915
The purpose of this study was to assess the prognostic value of F-FDG PET parameter variation between baseline and 42 Gy (PET2) of radiochemotherapy at 6 mo and 1 y...
2.
Lucibello F, Gounant V, Aldea M, Duruisseaux M, Perol M, Chouaid C, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100743.
PMID: 39850629
Introduction: Pralsetinib is a RET inhibitor found to have antitumor activity in advanced, metastatic, fusion-positive NSCLC. Objective: To assess real-world efficacy of pralsetinib and treatment sequences in patients with RET...
3.
Akli A, Takam Kamga P, Julie C, Capron C, Costantini A, Dumenil C, et al.
Cancer Immunol Immunother
. 2025 Jan;
74(2):58.
PMID: 39751636
Most of advanced non-small cell lung cancer (NSCLC) patients will experience tumor progression with immunotherapy (IO). Preliminary data suggested an association between high plasma HGF levels and poor response to...
4.
Mehlman C, Swalduz A, Monnet I, Morin C, Wislez M, Guisier F, et al.
Oncologist
. 2024 Dec;
PMID: 39724403
Introduction: The emergence of diverse resistance mechanisms after osimertinib therapy, including on-target epidermal growth factor receptor (EGFR) mutations and off-target alterations, warrants investigation of novel therapeutics to overcome these challenges...
5.
Vera P, Thureau S, Le Tinier F, Chaumet-Riffaud P, Hapdey S, Kolesnikov-Gauthier H, et al.
Lancet Oncol
. 2024 Aug;
25(9):1176-1187.
PMID: 39134086
Background: Thoracic radiation intensification is debated in patients with stage III non-small-cell lung cancer (NSCLC). We aimed to assess the activity and safety of a boost radiotherapy dose up to...
6.
Garinet S, Lupo A, Denize T, Loyaux R, Timsit S, Gazeau B, et al.
Pathology
. 2024 Jun;
56(5):702-709.
PMID: 38834439
Metastatic non-small-cell lung cancer (NSCLC) displays various molecular alterations in the RAS-MAPK pathway. In particular, NSCLCs show high rates of targetable gene fusion in ALK, RET, ROS1, NRG1 and NTRK,...
7.
Belaidi L, Wang P, Quintin K, Durdux C, Giroux-Leprieur E, Giraud P
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958302
Stereotactic radiotherapy (SRT) is gaining increasing importance in metastatic non-small-cell lung cancer (mNSCLC) management. The optimal sequence of tumor irradiation relative to systemic treatment remains unclear. If waiting response evaluation...
8.
Chour A, Denis J, Mascaux C, Zysman M, Bigay-Game L, Swalduz A, et al.
J Thorac Oncol
. 2023 May;
18(10):1408-1415.
PMID: 37217096
Introduction: Sequential anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) followed by small targeted therapy use is associated with increased prevalence of adverse events (AEs) in NSCLC....
9.
Schlemmer F, Valentin S, Boyer L, Guillaumot A, Chabot F, Dupin C, et al.
Eur Respir J
. 2023 Jan;
61(4).
PMID: 36669777
Background: Survivors of severe-to-critical coronavirus disease 2019 (COVID-19) may have functional impairment, radiological sequelae and persistent symptoms requiring prolonged follow-up. This pragmatic study aimed to describe their clinical follow-up and...
10.
Akli A, Girard N, Fallet V, Rousseau-Bussac G, Gounant V, Friard S, et al.
Target Oncol
. 2022 Sep;
17(6):675-682.
PMID: 36129569
Background: Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in first line for the treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Objective: The...